Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Regulatory rejection flurry does not make a storm
Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Merck & Co justifies paying up for Acceleron
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
